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Abstract
Data sharing in autism neuroimaging presents scientific, technical, and social obstacles. We
outline the desiderata for a data-sharing scheme that combines imaging with other measures of
phenotype and with genetics, defines requirements for comparability of derived data and
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recommendations for raw data, outlines a core protocol including multispectral structural and
diffusion-tensor imaging and optional extensions, provides for the collection of prospective,
confound-free normative data, and extends sharing and collaborative development not only to data
but to the analytical tools and methods applied to these data. A theme in these requirements is the
need to preserve creative approaches and risk-taking within individual laboratories at the same
time as common standards are provided for these laboratories to build on.
Keywords
Imaging; MRI; PET; Morphometry; Segmentation; Data sharing
The Problem
Tracing the behaviourally defined syndrome of autism to its neurobiological roots poses a
difficulty since autism is heterogeneous in terms of its detailed symptom profiles (Ronald,
Happé, & Plomin, 2005), genetic and environmental antecedents (Veenstra-Vanderweele,
Christian, & Cook, 2004) and developmental mechanisms (Belmonte et al., 2004a). Because
autism in this regard may be an amalgam of many unknown conditions, it seems a foregone
conclusion that behaviourally ascertained groups of subjects contain large amounts of
unmodelled variance, and that the relation between group size and statistical power is a steep
one (Coon, 2006). This problem of sample size in the context of heterogeneous conditions is
particularly acute in the domain of brain imaging, where costs are great and small samples
are therefore more accepted and more usual. A solution seems clear in principle: the many
small data sets collected by various investigators ought to be pooled into one large data set
for analysis. Several obstacles, though, make such data sharing easier said than done. These
obstacles are scientific, technical, and social—but not insurmountable.
The scientific obstacles are matters of sample heterogeneity, which complicate the
comparability of separately ascertained groups. This heterogeneity is both longitudinal and
cross-sectional. Longitudinally, especially given autism’s nature as a developmental
disorder, measurements can be expected to change over the course of maturation and aging
(Aylward, Minshew, Field, Sparks, & Singh, 2002; Carper, Moses, Tigue, & Courchesne,
2002). [The inconsistency of recent findings on the size of the amygdala at various ages is a
case in point (Baron-Cohen, Knickmeyer, & Belmonte, 2005).] The consequent need to
control and account for age particularly hampers retrospective efforts to combine separately
ascertained samples. Cross-sectionally, autism’s multiplicity of symptom profiles and
neurobiological mechanisms makes it imperative to correlate imaging with other measures
of potential endophenotypes, heightening the demand for large data sets which can be
fractionated according to such measures. In addition, autism is much more common in males
than in females, and sex differences extend to symptom profiles (McLennan, Lord, &
Schopler, 1993) and possibly to mechanisms (Baron-Cohen et al., 2005), making it
important to factor out sex as a variable, and magnifying the problem of sample size in the
case of the smaller, female subgroup.
The technical obstacles concern comparability of raw and derived data across scanners (Han
et al., 2006; Jovicich et al., 2006) and analytical methods, as well as the problem of storage
and retrieval of images and related subject variables. Adherence to fixed acquisition
strategies is complicated by variables such as the radiopharmaceutical ligand chosen for a
receptor of interest in PET, or the type of coil used in MRI or the type of crystal in PET.
Such factors and their associated tradeoffs make it difficult and inadvisable to require
absolute standards in very basic parameters such as MRI pulse sequence or PET attenuation
correction method. Even within individual studies, the pressure to adopt newer instruments
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is a well-known difficulty in longitudinal approaches. In addition to these sources of
variance in raw data, differences in analytical procedures including methods of segmentation
and measurement of tissues and structures introduce variation in derived measures. Finally,
once the data are acquired and analysed, an informatics challenge exists in the databasing
problem of storing and retrieving brain images (Van Horn, Grafton, Rockmore, &
Gazzaniga, 2004) and related subject information (Scahil & Lord, 2004).
These scientific and technical obstacles are well defined, and strategies can be and have
been devised to solve them. On a more abstract level, though, prospects for data sharing are
affected at least as much by social and cultural obstacles (Koslow, 2000). A reward structure
in which proposals are rated as to likelihood of success and ranked against each other
encourages productive competition, but often at the cost of potentially productive
cooperation and speculation. Investigators become biased towards “safe” approaches driven
by preconceived and conservative hypotheses, rather than “fishing expeditions” that take
advantage of the data-mining capacity of information technology. Furthermore, instead of
being shared freely, observations collected during these studies often are guarded zealously.
As a result, what’s best for an individual investigator does not always coincide with what’s
best for science. Though it is easy enough to get all the stakeholders to agree in principle
that this is a poor state of affairs, finding agreement on how to change it is more
problematic. Solutions imposed from the top down are likely to evoke opposition, or at least
lack of support, since such methods do not involve the expertise and concerns of the
individual scientists who are affected. A solution is most effective when all the people
affected have been afforded an opportunity to participate in defining it (Ury, 1993). The
field of autism research, and individual investigators within autism research, need a structure
that preserves competition’s benefits to scientific innovation (and to individual
advancement), but also facilitates cooperative and speculative research that otherwise would
be impossible.
Successes
A strategy for collecting, maintaining, and distributing shareable brain images in the context
of autism research can take inspiration from similar efforts in normative and clinical
populations. The Biomedical Informatics Research Network (BIRN) is developing technical
infrastructure and policy to support sharing of biomedical data, with a subgroup focusing
specifically on morphometric data. Collaborative MRI morphometric studies of depression,
Alzheimer’s disease, and mild cognitive impairment are used as test cases for the
development and application of analysis pipelines and strategies for data archiving and
retrieval (Jovicich et al., 2005). The project applies the grid computing model (Peltier &
Ellisman, 2004), in which computer networks function as links not only to data storage
facilities but to computational facilities, and the data analysis pathway is supplied to users
not as downloaded software to be run locally but rather as a network-based service.
The International Consortium for Brain Mapping (ICBM) (Mazziotta et al., 2001) is a
prospective study of 7,000 normal subjects with the goal of creating a probabilistic atlas of
the human brain, one that describes not only normal anatomical location but also normal
anatomical variation. The ICBM has structured itself in a way that promotes—and indeed
demands—solution of problems of data exchange and interoperability. The group
deliberately selected centres with different scanning hardware and computing systems, so
that data processing and archiving could not depend on any particular scanner characteristics
or single data format. Rather than specifying any specific pulse sequence or other
fundamental parameters related to scan acquisition, quality control is implemented in terms
of derivative properties such as tissue segmentability. The benefits of competitive
innovation are combined with a cooperative structure in which individual laboratories are
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free to develop their own algorithms for each stage of a pipeline of data processing, and
these competitive solutions are then compared and evaluated by an impartial judge. The
winning methods then become part of the standard ICBM processing pipeline, whilst
individual laboratories remain free to supplement this standard approach with their own
methods. Here again, the model of grid computing applies: raw scans can be uploaded to the
ICBM web site, where the standard processing pipeline can be applied to each.
The NIH MRI Study of Normal Brain Development (Evans, 2006) is another prospective
study of normal neuroanatomy. MR scans and spectroscopy data are collected at six
participating centres with uniform acquisition parameters, and these raw data are uploaded
to a central database maintained by a single coordinating centre. Tissue segmentation and
anatomical parcellation are performed at the coordinating centre, using components of the
ICBM analysis pipeline. Intensity histograms of the raw images are corrected for magnetic
field inhomogeneities which vary from centre to centre, and comparability of derived
measures is evaluated for many brain regions—a difficult issue since systematic contrast
differences within the raw data can translate to systematic differences in derived measures
such as cortical thickness. The study’s large sample will serve as a resource for involvement
of the wider MRI research community, and enables correlative morphometric studies
between anatomical regions, the anatomical analogue of functional connectivity measures.
In addition to large-scale normative studies, precedent exists for application of MRI data
sharing strategies to specific diseases. In 2002, the Tourette Syndrome Association (TSA)
convened a neuroimaging workshop, out of which grew the TSA International
Neuroimaging Consortium. The Consortium was built on the model established by the TSA
Consortium for Genetics and, therefore, could take advantage of an existing collaborative
network and subject database. The Consortium’s initial focus is to add structural imaging to
the genetic data already available. Later, after technical and sociological obstacles have been
addressed, functional imaging may be added.
Imperatives
The past few years’ surge of interest and activism has autism poised to become a major
focus of biomedical research. Whatever institutional structures are developed for this
activity will affect it for many years, and therefore it is crucial to manage these so that they
facilitate discovery and do not retard it.
Embracing Non-hypothesis-driven Resources
Funding agencies must recognise that in the age of data-mining technology, a deserving
proposal need not be exclusively driven by a specific hypothesis. Studies that aim to
establish collaborative resources and to explore unforeseen correlations within these data are
valuable even without—and in some cases especially without—a priori knowledge of the
directions in which the data may lead. Many research questions of great relevance to
neuropsychiatric and neurodevelopmental disorders—perhaps the majority of questions in
imaging—cannot be answered with the comparatively tiny samples attainable by individual
laboratories, and therefore demand such collaborative resources. To restrict our attention to
hypothesis-driven studies with narrow research backgrounds would be to deny the
informatics advances of the 21st century. Accordingly, study sections must stop focusing
exclusively on replying to specific hypotheses, and consider prioritising proposals that
establish bioinformatics resources applicable in hypothesis generation and testing. This
resource-driven approach is already considered valid in the case of tissue banks, and it
makes sense to extend it to collections not of physical brain tissue but of virtual brain
images. In this context of informatics resources, divergence of research interests and
approaches can be regarded as a potential asset, not as a liability. With regard to autism in
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particular, where heterogeneity is such a significant consideration, logical methods of
subgrouping will allow more intelligent querying of genetic and phenotypic data. A great
deal of information can be mined from the conjunction of genetic information with
neuroanatomical, behavioural, and other phenotypic data—even though such integrative
proposals all too often are derided as “underpowered” by reviewers familiar with only one
facet of the work. The conservative, hypothesis-driven approach of waiting for narrowly
focused experts to ascertain a specific genotypic or phenotypic signal, and only then
commencing exploration of possible genotype–phenotype correlations, is no longer the only
productive strategy. To hasten progress in autism research, funding agencies must augment
this focus with strategies that sweep up a breadth of observations. This imperative holds
especially in the current funding climate, in which competition is keen and funding agencies
may be tempted to seize on narrow and outdated criteria to exclude proposals from further
consideration. The Human Genome Project, for instance, never would have begun had it had
to pass the scrutiny of a traditional study section.
Combining Imaging with Genetic, Biochemical and Behavioural Assessments
A basis for such correlative work on autism already exists, in the form of the Autism
Genetic Resource Exchange (AGRE) (Geschwind et al., 2001). As of this writing, AGRE
contains data from more than 1,100 families, and is accessed by more than 135 researchers.
AGRE provides the highest quality of standardised data, and is the source for over a third of
the data in the Autism Genome Project. The resemblance of this picture to the state of the
TSA Consortium for Genetics in 2002 bodes well for a similar extension of AGRE to
neuroimaging, and we suggest that one of the first projects of a collaborative autism
neuroimaging network might be to image either the existing AGRE population or a new,
younger cohort that would be recruited prospectively into AGRE for longitudinal study.
Genotypic, biochemical and phenotypic characterisation will proceed faster when they are
not conducted in isolation from each other: known genetic polymorphisms can guide
searches for neuroanatomical correlates at the same time as neuroanatomical clustering can
identify subgroups for genetic analyses, and both can be correlated with endophenotyping
for mitochondrial abnormalities (e.g. lactate, pyruvate, carnitine), organic and amino acids,
lipid profile, oxidative stress markers and inflammatory cytokines, all of which have shown
abnormalities in autism (Johnston, 2000) and which may provide crucial links between the
widely separated levels of genetics on the one hand and neuroanatomy, neurophysiology,
and behaviour on the other. These correlative strategies can be applied not only within the
patient population but also in “unaffected” relatives and in the normal population: for
example, exploratory genetic studies could be targeted at relatives or even normal controls
whose brain volumes or behavioural measures lie in the tails of the distribution. Focusing on
these normal extremes may provide clues as to what to look for within the autism
population.
A key question in combining imaging with a genetic database is whether one should aim to
image probands only, or entire pedigrees, given financial and practical constraints on the
total number of scans that can be collected within the scope of the initial study. Imaging
probands only would of course be most efficient for identifying and characterising subtypes
within the diagnosis, and for evaluating anatomical phenotypes across the lifespan. On the
other hand, studying entire pedigrees is a more effective strategy for pursuing
endophenotypes which extend within and beyond the diagnosis (Belmonte et al., 2004b),
and well characterised genetic abnormalities within individual extended pedigrees may point
the way to gene networks relevant to autism. Given these opposing goals for
subphenotyping and longitudinal studies on the one hand and endophenotyping on the other,
we suggest a compromise in which half of the available scans are devoted to AGRE or other
pedigrees and half to singleton patients not necessarily associated with AGRE. Pedigree
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scans would include, at minimum, the proband, the most closely matched sib (if available),
and the parents. In order to maximise enrolment and to minimise attrition, participating
families must receive clear benefits, including interaction with a case worker, a summary of
results, and payment for their time (typically $200 per study, recognising that control
families may need more incentive to participate than do autism families) and for their travel
expenses.
The full value of these imaging data cannot be realised without a standardised and
comprehensive yet practical set of phenotypic measures. We have drafted such a standard,
presented in Table 1. In designing this phenotypic battery, we have considered all functional
domains affected in autism spectrum conditions, including non-diagnostic domains such as
motor and sensory function. We also hoped to include measures applicable to subclinical
traits in family members, and to the milder traits in some non-retarded people with autism
spectrum conditions. Thus we considered symptoms in degrees, rather than as the simple,
binary distinction of diagnosis or not. Of especial interest were variables with potential
significance for biological and genetic subtyping, such as regression onset, mode of
language development, presence of seizures, psychiatric comorbidity, and head
circumference. At the same time, since the spare time available to a family dealing with
autism is even more limited than that of a normal family, this standard battery cannot
practically include every test that may be of interest. The suggested test battery is minimal
and targets verbal school age and adult subjects. The battery could be modified for younger
and lower ability subjects or substantially expanded to address specific hypotheses.
Governance by and for the Affected Researchers
Such is the zeitgeist for collaborative resources that extension of a genetic resource such as
AGRE seems inevitable. The question, though, is whether this extension will be
accomplished in a way that preserves and augments the innovative capacity of independent
research groups, or whether it may create unnecessary strictures that suppress novel
approaches. AGRE is contributing its Internet System for Assessing Autistic Children
(ISAAC) (ISAAC) (Hollander et al., 2004) and all its clinical assessment data to the
National Database for Autism Research (NDAR), an NIH-sponsored effort to facilitate and
to promote sharing of all types of data in autism research. Though the spirit behind NDAR is
laudable, the organisers of NDAR must beware of dictating too many of the specifics, and
must be careful to solicit input from the researchers affected. Otherwise, the relationship
between NDAR and the research groups best positioned to conduct innovative studies may
develop into one of adversarial tension rather than cooperative support. In order to forestall
such a development, NDAR must actively solicit ongoing input from the autism research
community, perhaps by instituting a steering committee similar to that of AGRE, the
majority of whose membership consists of investigators for whom autism is a primary and
long-term focus of research. Where appropriate, input as to the goals and direction of NDAR
ought also to be solicited from representatives of the patient community. Though its goal of
data sharing enjoys broad support within the autism research community, without such a
participatory structure for its governance, NDAR itself may not gain acceptance from
autism researchers.
Data sharing requires not only agreement on standards for data comparability but also
agreements as to when or under what conditions the data from each individual laboratory
would be released for general use. Our experience suggests that such agreements are
attainable by individual investigators on a case-by-case basis. However, individual data sets
and research objectives may vary widely as to the resources invested in data collection and
the amount of time necessary to attain milestones in innovative or labour-intensive data
analyses. For example, young children and infants who must be imaged during sleep, and
people with low-functioning autism who may find it difficult to tolerate the scanner
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environment, consume many more resources (and many more late-night hours on the part of
investigators) than do adults or high-functioning cases. Furthermore, detailed, hand-traced
morphometric measurements demand a great deal more time for exclusive analysis within
the investigators’ own laboratory than do automated methods such as voxel-based
morphometry. Specific plans and timetables for data sharing must, therefore, be set by the
individual investigators as appropriate for their specific methodologies. Top-down efforts to
impose a uniform time limit on release of data are unlikely to succeed, and risk destroying
the incentive to collect data sets on the most difficult and valuable patient populations and
age groups.
Standards for Comparability of Derived Data
Collaborative imaging efforts within the CPEA/STA-ART research community stand in
contrast to NDAR in that they are led by the researchers themselves. Such efforts are
sometimes slow to overcome initial obstacles, but in the end may achieve greater staying
power. One of the first collaborations to emerge from this community is the Pooled MRI
Data Project, an effort to combine data at the derived level of morphometric measures with
an accounting for site-specific variance in these measures. The Pooled MRI Data Project
comprises data from 18 projects at 15 sites, with an expected total of approximately 1,200
cases, half autism-spectrum and half normal controls. Combined data will be analyzed for 18
specific brain regions, with particular attention to differences in developmental changes
between the two groups. Methods for performing measurements are being evaluated to
determine whether data from each site have been collected in such a way that they are
reasonably comparable to data from other sites. Analyses will include site as a covariate to
adjust for minor differences in measurement technique. In addition, demographic, clinical,
and neuropsychological data are being collected so that homogeneity of samples across sites
can be assessed and analyses can be based on subgrouping.
Though the Pooled MRI Data Project is only a beginning, it exemplifies the perspective
amongst autism researchers that a data sharing project can usefully focus on establishing
comparability of derived measures even when characteristics of the raw data vary. Such
comparability can be established by quality control procedures applied both within sets of
raw images and across sets of derived quantities. Raw quality control should include
measures general enough to make sense in application to all sets of scan parameters, such as
signal-to-noise and contrast-to-noise. Derived measures can include segmented tissue
volumes, landmarking and parcellation, structure volumes, and fibre maps in a set of
standard subjects (“living phantoms”) scanned at multiple sites. Validity of automated
landmarking and parcellation could be established with reference to “gold standard”
measures, many of which already exist as by-products of studies of specific cortical and
subcortical structures in autism (Aylward et al., 2002; Carper et al., 2002). These standards
can be refined in collaboration with an independent expert in neuroanatomy. Such
procedures can establish data comparability without corralling investigators into protocols
that may be inappropriate to their specific scanning hardware or research foci. Recognising
the usefulness of standards for comparability at higher levels of data abstraction, funding
agencies need not compel investigators to justify every deviation from recommended
standards for raw data acquisition.
Though it may be tempting to save scanning costs by assuming comparability of data from
existing normative studies, to rely on such an assumption may introduce serious
methodological confounds. Strategies for establishing data comparability despite variations
in acquisition and processing are not applicable in designs where the experimental factor of
subject group is confounded with such variations. If each centre studies some autism
subjects and some normal subjects, then cross-centre variation can be controlled and
modelled, rendering the data comparable. If, though, the autism subjects are exclusive to one
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group of centres and the normal subjects to another, as is the case when prior normative
studies are used as comparisons, then variation across centres is fundamentally confounded
with variation between experimental groups. The results from such a study would be
worthless since the effects of group and the effects of centre could not be disambiguated. In
addition, for studies addressing autism in particular, prior normative studies may not have
supplemented their imaging data with appropriate phenotypic and genotypic measures and
therefore would be less useful comparisons in any case. Therefore, at the same time as new
images are acquired for autism subjects, similar data on normal comparison subjects must be
acquired at the same centres using the same acquisition and processing strategies. Such a
strategy retains the opportunity to leverage preexisting normative databases by
demonstrating the comparability (reliability) of such data with new control data specifically
acquired for studies of autism. Nevertheless, retrospective comparison against a normative
database is not a complete substitute for prospective acquisition of new control data.
A Core Protocol with Optional Extensions
Given differences in scanners, the varying technical demands of site-specific research aims,
and ongoing developments in MR protocols, it would be impractical to require an inflexible
imaging protocol for use by all studies within an imaging consortium. Fortunately, such an
absolute standard for comparability of raw data, though helpful, is not essential to
comparability of derived measures. Whereas prospective collaborations can and should
recommend protocols that yield the highest degree of comparability in the raw data, they
need require comparability only at the level of derived data. Such comparability must be
demonstrated by pilot data evaluated on raw and derived measures—at a minimum, signal-
to-noise, contrast-to-noise, and automated tissue segmentation results, and maintained by
ongoing quality control procedures on physical phantoms, living subjects, and incoming data
sets. A core protocol ought to include recommendations for high-resolution anatomical
imaging and diffusion-tensor imaging, whose specific implementations at each site would
yield comparable derived data and largely compatible raw data. This core protocol ought to
consume at most 1 h of imaging time, bearing in mind that each individual group of
investigators will have their own, site-specific adjuncts to their implementation of the core
protocol. In addition, optional protocols may be specified for magnetic resonance
spectroscopy, magnetisation transfer imaging, arterial spin labelling, PET, fMRI, and EEG/
ERP studies. Support for these core and optional protocols should be provided by a
collaborative technical group which would meet regularly. Given the difficulties of inferring
developmental courses and endophenotypes from cross-sectional observations (Kraemer,
Yesavage, Taylor, & Kupfer, 2000), subjects should receive longitudinal follow-up if
resources allow.
Diffusion tensor imaging (DTI), though still an evolving technique, is included in the core
protocol because of its strong relevance to autism’s neuroanatomical abnormalities of white
matter growth and neurophysiological abnormalities of functional connectivity. DTI exploits
the observation that water molecules diffuse more freely along axons than across axonal
membranes and myelin sheaths. The direction of diffusion can be determined by collecting a
set of MR images sensitive to diffusion in different directions. The direction of diffusion,
expressed as a tensor, is calculated using least squares minimisation (Basser & Pierpaoli,
1996), and visualised as colour-coded displays of fibre orientation (Pajevic & Pierpaoli,
1999). Initial DTI results on autism have indicated reductions in diffusion anisotropy in
white matter communicating with brain regions implicated in social and complex processing
(Barnea-Goraly et al., 2004).
Proton magnetic resonance spectroscopy (1H MRS) has been used to detect cellular
abnormalities in brain regions that appear normal in MRI, as well as to elucidate cellular
pathology underlying MRI-visible abnormalities. Using standard clinical MRI scanners, 1H
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MRS can measure brain tissue concentration and mobility of neurochemicals such as choline
(Cho), creatine, (Cre), N-acetylaspartate (NAA), myoinositol (mI), glutamate + glutamine
(Glx) and lactate, providing information on membrane turnover, tissue energetic status and
neuronal and glial cell viability. Some—though not all—MRS studies of autism have
yielded evidence of differences in tissue maturation or neuronal integrity, either generalised
or specific to distinct developmental age points or brain regions. In this context, and because
common 1H MRS tools are available on most clinical scanners, single-voxel MRS is
specifically proposed as an optional extension to the core imaging protocol. A recommended
protocol for single-voxel proton MRS at short echo time (on the order of 20–30 ms), using a
widely available pulse sequence (such as PRESS), would entail standardised voxel
placement in regions of interest such as right medial temporal lobe, right parieto-occipital
white matter region, right frontal lobe, and cerebellum. To ensure comparability across sites,
each voxel acquisition would require a similar water scan (same echo time) for metabolite
quantification. Each combined metabolite/water voxel acquisition would take on the order of
10 min including placement, set-up and acquisition. Total time requirements would depend
on the number of regions sampled but are clinically feasible for a cooperative (or sedated)
subject.
Instantiating the Protocol in Future Studies
In Table 2 we outline in very general terms a possibity for a future study based on the
protocol that we have described. The aforementioned objectives of endophenotypes within
autism families and subphenotypes across the autism population are balanced by selecting
half the study population from probands and their first-degree relatives (at a minimum, the
parents and the most closely matched sib) in AGRE, and the other half from autism
probands at participating centres. The study would include patients from birth to 40 years of
age, across the full spectrum of autism symptoms and IQ levels. In light of results on
abnormal brain growth and white matter enlargement (Courchesne, Redcay, & Kennedy,
2004), the core imaging protocol attempts to define further autism’s structural phenotype,
both in whole brain and specifically in white matter with a focus on DTI and magnetisation
transfer. We aim also to include measures of brain function, without over-specifying the
particular functional protocols (a topic perhaps best left for a separate consensus statement).
Functional assays could include complementary fMRI and EEG measures in an agreed set of
behavioural tasks spanning social domains (e.g. face and emotion recognition) and non-
social domains (e.g. attention and perception), and also PET applied for selected ligands, the
receptor systems to be determined only at the time when studies actually commence and
insights as to the best choices would be enhanced. To enable meta-analyses across diagnoses
but within symptom complexes, clinical and imaging protocols should include features of
overlap with patients with Rett syndrome, Fragile X syndrome, Tourette syndrome and
possibly others. Although the scope of data collection is limited by subject tolerance, costs,
and in some cases radiation exposure, if resources allow then subjects would receive
longitudinal follow-up. A small number (2–3) imaging sites should be selected for proximity
to the AGRE population and, most importantly, imaging expertise.
Sharing of Analytical Methods, Tools, and Processing
The informatic and neuroscientific work of data analysis represents a significant portion of
experimental effort, over and above the clinical work of subject assessment and data
acquisition. Though the research community strives for automation for reasons both of
throughput and of reproducibility, the fact remains that MR image analysis never is as
simple as pushing a button. Implementing and tuning data analysis strategies requires a
considerable amount of algorithmic design, computer programming, and technical
documentation—efforts that often are designed around specific, single experiments or
research questions and cannot be generalised to other applications, and whose full potential
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therefore goes unrealised. Rather analogously to the problem of underpowered imaging
studies with small samples and incompatible protocols, the lack of cooperation and
standardisation in analytical methods has produced a slew of software that is
ungeneralisable, and often incomprehensible except to its authors and their own laboratory
groups. This problem of duplication and insufficient generalisability can be addressed if
schemes for sharing encompass not only the data but also the methods and tools applied to
the data. One success story in this regard is the Insight Toolkit (Yoo & Metaxas, 2005), an
applications programming interface for high-dimensional image processing which arose
from a collaborative workshop on the Visible Human Project.
One way to implement shared analytical tools is to develop, test, and disseminate a
standardised “core” data analysis pipeline, much as the ICBM have done, drawing on
competitive input from all interested participants. However, by the same rationale we have
developed in previous sections of this paper, innovative methods for image analysis that go
beyond this pipeline also should be strongly encouraged. This bottom-up approach to
innovation will enhance the generation of novel, important findings from new studies and
investigators. Depending on processing demands and local computational resources,
elements of the pipeline can be made available via downloads of software for processing at
local sites, or via uploads of data for processing in a grid computing environment. Of course,
uploading one’s data to the grid for processing need not imply immediately releasing one’s
exclusive interest in those data; schedules and conditions for release of data can be defined
in individual cases, as noted above, and sharing of analytical resources and methods need
not be simultaneous with sharing of data.
The technical, scientific, and social obstacles make data sharing a difficult problem, but the
complexity and heterogeneity of autism make data sharing an imperative if researchers are
to make headway. Fundamentally, therefore, data sharing will be a benefit both for the field
as a whole and for the individuals involved in building it. A successful scheme will combine
imaging with other phenotypic and genetic data to exploit correlations across these levels of
analysis and to build endophenotypes, will extend to sharing of analytical tools, and will
encourage cooperation without discouraging the creative efforts and strategies of
individuals.
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Table 1
Autism imaging phenotype battery for probands and relatives
Test or measure Source Time
Demographics
Birth date, sex, race, ethnicity, SES, years of education, intervention history 5
Diagnostics
Autism Diagnostic Interview—Revised (Lord, Rutter, & Le Couteur, 1994) WPS 120–180*
Autism Diagnostic Observation Schedule—Generic (Lord et al., 2000) WPS 45–60
Mode of onset: delays, regression, both, or unknown
Language and speech: clearly precocious or undelayed, clearly delayed, or not
known
Ability level
 Choose one or more according to ability level, testing time, investigator
preference:
  Raven’s Coloured Progressive Matrices Harcourt 20
  Differential Abilities Scale (ages 2:6–17) Harcourt 45–65
  Mullen Scales of Early Learning (ages 0–5:8) AGS 40–60
  WISC-IV (ages 6–16) Harcourt 90
  WAIS-III (ages 16–89) Harcourt 90
  WASI (ages 6–89) Harcourt 50–60
  Stanford-Binet Intelligence Scales (ages 2–85+) Riverside 75–90
Vineland Adaptive Behaviour Scales II (Survey Interview) AGS 20–30*
Current levels of language and speech
Clinical Evaluation of Language Fundamentals (CELF-4) Harcourt 30–60
Peabody Picture Vocabulary Test (PPVT-4) AGS 10–25
Expressive Vocabulary Test (EVT) AGS 20
Oral and Written Language Scales (OWLS) AGS/WPS 10–30
Test of Language Competence (TLC-E) Harcourt 60




Continuous Performance Test II Harcourt 14
Executive function
Wisconsin Card Sorting Test PAR 20
Delis-Kaplan Tower Test Harcourt 10
Behavioral Assessment of the Dysexecutive Syndrome (BADS) Harcourt 40
Working memory: spatial and verbal
Wide Range Assessment of Memory and Learning (2nd ed.) Finger Windows PAR 10
Detroit Tests of Learning Aptitude, Oral Directions subtest Harcourt 5
Associative memory
Wechsler Memory Scale subtests Harcourt
 Paired Associate Learning (Verbal or Visual) 10
 Story Recall, immediate and delayed recall 20
Porteus Maze Harcourt 15–20
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Test or measure Source Time
Social cognition
Social Responsiveness Scale (SRS) (Constantino et al., 2003) WPS 10–15*
Reading the Mind in the Eyes Test (Baron-Cohen, Wheelwright, Hill, Raste, &
Plumb, 2001)
Cambridge Autism Research Centre 10
Benton Facial Recognition Test PAR 10–15
Sensorimotor function
Edinburgh Handedness Inventory or Oldfield Handedness Interview, Oldfield (1971) 5
Reitan-Klove Sensory Perceptual Examination (Reitan & Wolfson, 1985) 5
Halstead-Reitan Finger Tapping Test (Reitan & Wolfson, 1985) 10
Purdue Grooved Pegboard Test 3–5
Grip Strength Test 5
Sensory Sensitivity and Distortions Questionnaire (Minshew & Meyer, 2007) Pittsburgh Autism Research Project 10–15*
Repetitive Behaviour Scale—Revised (RBS-R) (Bodfish, Symons, Parker, & Lewis,
2000)
UNC Department of Psychiatry 10*
Physical and neurological examination
CPEA/STAART Medical and Psychiatric History Form CPEA/STAART Common Measures and
Data Sharing Committee
30*
Height, weight, head circumference 5
Screening for tuberous sclerosis, dysmorphic features, strabismus 10





Zygosity testing (for twins)
Pedigree construction
Comorbidity
Autism Co-morbidity Interview—Present & Lifetime Utah–Boston CPEA 60–120*
 Version (Tadevosyan-Leyfer et al., in press)
 Choose any appropriate for reported symptoms:
 Family Self-Report Questionnaire for Tics, Obsessive-Compulsiveness,
Attentional Difficulties, Impulsivity, and Motor Hyperactivity
Tourette Syndrome Association 30*
 Developmental Behaviour Checklist—Primary Carer Version (DBC-P) WPS 10–15*
 Child (or Adult) Symptom Inventory 4—Parent Checklist (CSI-4) Checkmate Plus 10–15*
 Pediatric Sleep Questionnaire U. Michigan Sleep Disorders Center 10
Family history
Medical history, including affective, anxiety, seizure, gastrointestinal, immune or
other disorders
30–45*
Broader Phenotype Autism Symptom Scale (BPASS) (Dawson et al., in press) UW Autism Center 60–90
Social Responsiveness Scale (SRS) WPS 10–15*
The battery is designed with older verbal children and adults in mind. It can be adapted for younger or less testable individuals (for instance, in
choices between verbal and visual tests), and/or expanded to focus on specific issues or hypotheses. Testing times are in minutes. Items marked
with an asterisk are parent or caregiver interviews. As many tests are optional or alternative, testing times in this table are not additive
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Table 2
Outline of a strategy for autism brain imaging, conforming to the core protocol described in the text and
balancing endophenotyping with subphenotyping
Study population
Birth—40 years
500 from AGRE families (probands and relatives), 500 singleton probands, 1,000 normal controls
All subjects
Multi-spectral structural MRI (T1, T2, proton density)
Diffusion Tensor Imaging
Selected subjects at specific sites
1H MRS (PRESS)
PET
fMRI (BOLD or arterial spin labelling)
EEG
Magnetisation Transfer MRI
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